Ibrahim Babangida Abubakar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ibrahim Babangida Abubakar has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Aliyu Muhammad
Department of Biochemistry, Ahmadu Bello University, Zaria, Nigeria
11 shared publications - Hwei-San Loh
School of Biosciences, University of Nottingham Malaysia, Jalan Broga, 43500, Semenyih, Selangor, Malaysia
9 shared publications Ibrahim Malami
Department of Pharmacognosy and Ethnopharmacy, Faculty of Pharmaceutical Sciences, Usmanu Danfodio University, Sokoto, Nigeria
7 shared publications- Ibrahim Malami
Usmanu Danfodiyo University
7 shared publications - Ilemobayo Victor Fasogbon
Department of Biochemistry, Faculty of Biomedical Sciences Kampala International University ‐ Western Campus Ishaka Uganda
5 shared publications - Patrick Maduabuchi Aja
Department of Biochemistry Bushenyi Western Region Kampala International University - Western Campus
5 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 412
Exploring the use of phytotherapy in benign prostatic hyperplasia [BPH]: a systematic review
Background Benign prostatic hyperplasia [BPH] is a prevalent condition among aging men, characterized by prostate gland enlargement leading to lower urinary tract symptoms [LUTS]. Conventional treatments like alpha-blockers and 5-alpha-reductase inhibitors, though effective, often result in adverse effects. This has spurred interest in phytotherapy, leveraging plant-derived compounds to mitigate BPH symptoms due to their safety, cost-effectiveness, and patient preference. Method A literature search was conducted across PubMed, Scopus, and Google Scholar for articles published up to June 2024 using PRISMA 2020 guidelines. Eligible studies involve preclinical models of BPH, interventions specifically targeting plant or plant-based therapy, quantitative outcomes related to BPH treatment and ameliorations, and studies with clear methodology and reporting of the administration and plant-based products. Results The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Conclusion Phytotherapy holds significant potential in BPH management, offering symptom relief with minimal side effects. While promising, further robust clinical trials are essential to validate efficacy, establish standardized protocols, and ensure integration into mainstream therapeutic frameworks.
- 20 February 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 412
Open AccessExploring the use of phytotherapy in benign prostatic hyperplasia [BPH]: a systematic review
Background Benign prostatic hyperplasia [BPH] is a prevalent condition among aging men, characterized by prostate gland enlargement leading to lower urinary tract symptoms [LUTS]. Conventional treatments like alpha-blockers and 5-alpha-reductase inhibitors, though effective, often result in adverse effects. This has spurred interest in phytotherapy, leveraging plant-derived compounds to mitigate BPH symptoms due to their safety, cost-effectiveness, and patient preference. Method A literature search was conducted across PubMed, Scopus, and Google Scholar for articles published up to June 2024 using PRISMA 2020 guidelines. Eligible studies involve preclinical models of BPH, interventions specifically targeting plant or plant-based therapy, quantitative outcomes related to BPH treatment and ameliorations, and studies with clear methodology and reporting of the administration and plant-based products. Results The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Conclusion Phytotherapy holds significant potential in BPH management, offering symptom relief with minimal side effects. While promising, further robust clinical trials are essential to validate efficacy, establish standardized protocols, and ensure integration into mainstream therapeutic frameworks.
- Open Access
- 20 October 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 1141
Turning a controversial plant into a health asset: Policy options for harnessing Catha edulis against hyperlipidemia
Cardiovascular diseases driven by hyperlipidemia are leading causes of death globally, with low- and middle-income countries carrying a disproportionate burden. Although statins continue to be the cornerstone of cholesterol therapy, unmet demands are sustained by cost, intolerance, and residual risk, especially in sub-Saharan Africa. When made as standardized extracts, Catha edulis, which has long been controversial due to its psychotropic alkaloids, is being explored more and more for its effects on metabolism. Improvements in lipid profiles (decreased low density lipoprotein-cholesterol and triglycerides, and increased high density lipoprotein-cholesterol), regulation of adipokines (decreased leptin and increased adiponectin) in high-fat diet animals are reported in preclinical study with lyophilized leaf extract. Gas chromatography–mass spectrometry and molecular docking implicate non-alkaloid phytochemicals that bind lipid-regulating targets, showing statin-like interactions with HMG-CoA Reductase. However, regular khat chewing is also linked to hepatic and cardiovascular problems in clinical and case-series research, highlighting an important difference between recreational exposures and regulated, standardized medication formulations. Standardization of extract manufacturing, regulatory pathways that distinguish medicinal from recreational use, ethically sound clinical trials, pharmacovigilance, and culturally sensitive communication are some of the policy options for African health systems that are outlined in this brief, which also summarizes the scientific evidence and clarifies the risks and benefits. With strict protections, Catha edulis may transform from a public health risk to a focused adjuvant in the treatment of dyslipidemia, particularly in areas where access to cutting-edge lipid-lowering medications is still a problem.
- 20 October 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 1141
Open AccessTurning a controversial plant into a health asset: Policy options for harnessing Catha edulis against hyperlipidemia
Cardiovascular diseases driven by hyperlipidemia are leading causes of death globally, with low- and middle-income countries carrying a disproportionate burden. Although statins continue to be the cornerstone of cholesterol therapy, unmet demands are sustained by cost, intolerance, and residual risk, especially in sub-Saharan Africa. When made as standardized extracts, Catha edulis, which has long been controversial due to its psychotropic alkaloids, is being explored more and more for its effects on metabolism. Improvements in lipid profiles (decreased low density lipoprotein-cholesterol and triglycerides, and increased high density lipoprotein-cholesterol), regulation of adipokines (decreased leptin and increased adiponectin) in high-fat diet animals are reported in preclinical study with lyophilized leaf extract. Gas chromatography–mass spectrometry and molecular docking implicate non-alkaloid phytochemicals that bind lipid-regulating targets, showing statin-like interactions with HMG-CoA Reductase. However, regular khat chewing is also linked to hepatic and cardiovascular problems in clinical and case-series research, highlighting an important difference between recreational exposures and regulated, standardized medication formulations. Standardization of extract manufacturing, regulatory pathways that distinguish medicinal from recreational use, ethically sound clinical trials, pharmacovigilance, and culturally sensitive communication are some of the policy options for African health systems that are outlined in this brief, which also summarizes the scientific evidence and clarifies the risks and benefits. With strict protections, Catha edulis may transform from a public health risk to a focused adjuvant in the treatment of dyslipidemia, particularly in areas where access to cutting-edge lipid-lowering medications is still a problem.
- Open Access
- 19 September 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 951
Impact of antibiotics on the genomic expression of Pseudomonas aeruginosa in the East African community: a systematic review
Introduction Antimicrobial resistance (AMR) is a major global health concern, with the greatest burden observed in lower-middle-income countries. Monitoring AMR through a One Health approach is essential to understand the link between clinical, animal, and environmental sources and to develop targeted interventions. Objectives This systematic review aimed to assess the impact of antibiotics on gene expression in Pseudomonas spp. within the East African Community (EAC). Methodology A thorough literature search across Web of Science, Scopus, and PubMed yielded 284 articles, of which 11 met the inclusion criteria after screening. The selected studies came from five EAC countries. Findings showed a high prevalence of AMR in Pseudomonas aeruginosa , with over 90% resistance to most antibiotics, except Amikacin, which remained effective likely due to limited usage. Results and discussion Common resistance genes identified included carbapenemases such as blaNDM-1 and blaVIM. The disc diffusion method was the most commonly used technique (50%).Multidrug-resistant clones like ST244 and ST357 were frequently reported. Environmental isolates had lower resistance rates (54%) compared to clinical strains (73%), suggesting differing selection pressures. Most studies originated from Kenya and Uganda (each 30%), reflecting differences in research capacity and healthcare infrastructure across the region. Conclusion These results underscore the urgent need for expanded AMR surveillance, stronger antimicrobial stewardship, and further research to inform public health responses in East Africa.
- 19 September 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 951
Open AccessImpact of antibiotics on the genomic expression of Pseudomonas aeruginosa in the East African community: a systematic review
Introduction Antimicrobial resistance (AMR) is a major global health concern, with the greatest burden observed in lower-middle-income countries. Monitoring AMR through a One Health approach is essential to understand the link between clinical, animal, and environmental sources and to develop targeted interventions. Objectives This systematic review aimed to assess the impact of antibiotics on gene expression in Pseudomonas spp. within the East African Community (EAC). Methodology A thorough literature search across Web of Science, Scopus, and PubMed yielded 284 articles, of which 11 met the inclusion criteria after screening. The selected studies came from five EAC countries. Findings showed a high prevalence of AMR in Pseudomonas aeruginosa , with over 90% resistance to most antibiotics, except Amikacin, which remained effective likely due to limited usage. Results and discussion Common resistance genes identified included carbapenemases such as blaNDM-1 and blaVIM. The disc diffusion method was the most commonly used technique (50%).Multidrug-resistant clones like ST244 and ST357 were frequently reported. Environmental isolates had lower resistance rates (54%) compared to clinical strains (73%), suggesting differing selection pressures. Most studies originated from Kenya and Uganda (each 30%), reflecting differences in research capacity and healthcare infrastructure across the region. Conclusion These results underscore the urgent need for expanded AMR surveillance, stronger antimicrobial stewardship, and further research to inform public health responses in East Africa.
- Open Access
- 5 September 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 877
Integrated Assessment of Antioxidant Defense, Phytohormonal Responses, and Rhizomicrobial Dynamics in Maize Cultivated on Heavy Metal Impacted Mining Soils, Kilembe, Uganda.
Background Heavy metal contamination of agricultural soils, particularly from mining activities, poses serious risks to food safety and public health. At the Kilembe mining site in Uganda, elevated levels of heavy metals have been reported in soils where maize ( Zea mays L.) is widely cultivated. This study investigated the biochemical stress response and culturable rhizobacteria in maize grown in heavy metal-contaminated soils to understand their mechanisms of adaptation. Methods Maize seeds were planted on farms obtained at varying distances from the Kilembe mining site (0, 1, 3, and 5 km) and a control site in Bushenyi (95 km), serving as groups 1-5, respectively. Oxidative stress and hormone profiles of germinated leaves and rhizospheric bacterial composition were determined using standard analytical and microbiological methods. Results Maize plants near the site had higher malondialdehyde levels and lower antioxidant enzyme activities (superoxide dismutase, catalase, and glutathione peroxidase). Brassinosteroid levels increased at 0 km, whereas auxin and abscisic acid levels decreased significantly across all distances compared to the control. Bacillus sp. was dominant at 39.71%, and Acinetobacter sp. was the least abundant (1.47%). The 3 km site had the highest bacterial load, while the 0 km site had high counts at lower dilutions. Plant growth-promoting rhizobacteria ( Bacillus sp. , Staphylococcus sp. , and Klebsiella sp. ) were highly distributed across sites. Conclusion The study showed that the presence of plant growth-promoting rhizobacteria, such as Bacillus spp., which were dominant, provided insight into the role of these rhizospheric organisms in conferring tolerance and is a probable adaptive mechanism that ensures the survival of maize plants grown around mining-associated farmlands, as seen in Kilembe, Uganda.
- 5 September 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 877
Open AccessIntegrated Assessment of Antioxidant Defense, Phytohormonal Responses, and Rhizomicrobial Dynamics in Maize Cultivated on Heavy Metal Impacted Mining Soils, Kilembe, Uganda.
Background Heavy metal contamination of agricultural soils, particularly from mining activities, poses serious risks to food safety and public health. At the Kilembe mining site in Uganda, elevated levels of heavy metals have been reported in soils where maize ( Zea mays L.) is widely cultivated. This study investigated the biochemical stress response and culturable rhizobacteria in maize grown in heavy metal-contaminated soils to understand their mechanisms of adaptation. Methods Maize seeds were planted on farms obtained at varying distances from the Kilembe mining site (0, 1, 3, and 5 km) and a control site in Bushenyi (95 km), serving as groups 1-5, respectively. Oxidative stress and hormone profiles of germinated leaves and rhizospheric bacterial composition were determined using standard analytical and microbiological methods. Results Maize plants near the site had higher malondialdehyde levels and lower antioxidant enzyme activities (superoxide dismutase, catalase, and glutathione peroxidase). Brassinosteroid levels increased at 0 km, whereas auxin and abscisic acid levels decreased significantly across all distances compared to the control. Bacillus sp. was dominant at 39.71%, and Acinetobacter sp. was the least abundant (1.47%). The 3 km site had the highest bacterial load, while the 0 km site had high counts at lower dilutions. Plant growth-promoting rhizobacteria ( Bacillus sp. , Staphylococcus sp. , and Klebsiella sp. ) were highly distributed across sites. Conclusion The study showed that the presence of plant growth-promoting rhizobacteria, such as Bacillus spp., which were dominant, provided insight into the role of these rhizospheric organisms in conferring tolerance and is a probable adaptive mechanism that ensures the survival of maize plants grown around mining-associated farmlands, as seen in Kilembe, Uganda.
- Open Access
- 8 April 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 412
Exploring the use of phytotherapy in benign prostatic hyperplasia [BPH]: a systematic review
Background Benign prostatic hyperplasia [BPH] is a prevalent condition among aging men, characterized by prostate gland enlargement leading to lower urinary tract symptoms [LUTS]. Conventional treatments like alpha-blockers and 5-alpha-reductase inhibitors, though effective, often result in adverse effects. This has spurred interest in phytotherapy, leveraging plant-derived compounds to mitigate BPH symptoms due to their safety, cost-effectiveness, and patient preference. Method The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Results The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Conclusion Phytotherapy holds significant potential in BPH management, offering symptom relief with minimal side effects. While promising, further robust clinical trials are essential to validate efficacy, establish standardized protocols, and ensure integration into mainstream therapeutic frameworks.
- 8 April 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 412
Open AccessExploring the use of phytotherapy in benign prostatic hyperplasia [BPH]: a systematic review
Background Benign prostatic hyperplasia [BPH] is a prevalent condition among aging men, characterized by prostate gland enlargement leading to lower urinary tract symptoms [LUTS]. Conventional treatments like alpha-blockers and 5-alpha-reductase inhibitors, though effective, often result in adverse effects. This has spurred interest in phytotherapy, leveraging plant-derived compounds to mitigate BPH symptoms due to their safety, cost-effectiveness, and patient preference. Method The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Results The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Conclusion Phytotherapy holds significant potential in BPH management, offering symptom relief with minimal side effects. While promising, further robust clinical trials are essential to validate efficacy, establish standardized protocols, and ensure integration into mainstream therapeutic frameworks.
- Open Access
- 7 April 2025
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 31 (2) , 144-150
Chloroform Fraction of Mitracarpus hirtus Induces p53-Mediated Cell Cycle Arrest and Apoptosis in MCF-7 Breast Cancer Cells
Background: Breast cancer remains a serious life-threatening disease to women worldwide, contributing to a high rate of mortality among women. A critical molecular event implicated in breast cancer progression is the dysregulation of the tumour suppressor gene p53, which plays a key role in DNA repair and the regulation of the cell cycle and proliferation of cells. Mitracarpus hirtus, traditionally used to treat various ailments, presents a largely untapped resource of agents with promising anti-cancer potential. This study examined the anti-breast cancer properties of the chloroform fraction of M. hirtus, with particular emphasis on the regulation of p53 upstream and downstream target genes. Methods: The leaves of M. hirtus were extracted and fractionated using solvents with increasing polarity to obtain hexane, chloroform and water fractions. Anti-proliferative effects of chloroform fraction were evaluated on MCF-7 cells using a neutral red assay. Cell cycle progression and apoptosis were analysed using flow cytometry with PI and Annexin V-7AAD staining, respectively. Real-time PCR was used to assess the expression profiles of apoptotic-related genes. Results: The results revealed a significant inhibition of MCF-7 cell growth by the chloroform fraction of M. hirtus (IC50 = 9.54 µg/mL). This fraction induced apoptosis in MCF-7 cells, increasing the population of cells in the early and late apoptotic stages. The pro-apoptotic genes p53, Bax, and Casp3 were upregulated, while the anti-apoptotic gene Bcl2 was downregulated. Additionally, UCK2 and STAT3 gene suppression was observed, with STAT3 showing the most significant change. The fraction also significantly inhibited cell cycle progression, causing an accumulation of cells in the G0/G1 phase. Conclusion: Our study shows the ability of M. hirtus to inhibit breast cancer cell growth and induce apoptosis, presenting promising opportunities for further research in breast cancer treatment.
- 7 April 2025
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 31 (2) , 144-150
Open AccessChloroform Fraction of Mitracarpus hirtus Induces p53-Mediated Cell Cycle Arrest and Apoptosis in MCF-7 Breast Cancer Cells
Background: Breast cancer remains a serious life-threatening disease to women worldwide, contributing to a high rate of mortality among women. A critical molecular event implicated in breast cancer progression is the dysregulation of the tumour suppressor gene p53, which plays a key role in DNA repair and the regulation of the cell cycle and proliferation of cells. Mitracarpus hirtus, traditionally used to treat various ailments, presents a largely untapped resource of agents with promising anti-cancer potential. This study examined the anti-breast cancer properties of the chloroform fraction of M. hirtus, with particular emphasis on the regulation of p53 upstream and downstream target genes. Methods: The leaves of M. hirtus were extracted and fractionated using solvents with increasing polarity to obtain hexane, chloroform and water fractions. Anti-proliferative effects of chloroform fraction were evaluated on MCF-7 cells using a neutral red assay. Cell cycle progression and apoptosis were analysed using flow cytometry with PI and Annexin V-7AAD staining, respectively. Real-time PCR was used to assess the expression profiles of apoptotic-related genes. Results: The results revealed a significant inhibition of MCF-7 cell growth by the chloroform fraction of M. hirtus (IC50 = 9.54 µg/mL). This fraction induced apoptosis in MCF-7 cells, increasing the population of cells in the early and late apoptotic stages. The pro-apoptotic genes p53, Bax, and Casp3 were upregulated, while the anti-apoptotic gene Bcl2 was downregulated. Additionally, UCK2 and STAT3 gene suppression was observed, with STAT3 showing the most significant change. The fraction also significantly inhibited cell cycle progression, causing an accumulation of cells in the G0/G1 phase. Conclusion: Our study shows the ability of M. hirtus to inhibit breast cancer cell growth and induce apoptosis, presenting promising opportunities for further research in breast cancer treatment.
- Open Access
- 9 January 2025
- Published by Oxford University Press (OUP) in Biology Methods and Protocols
- Vol. 10 (1)
Advances and future directions of aptamer-functionalized nanoparticles for point-of-care diseases diagnosis
Point-of-care (POC) diagnostics have revolutionized disease detection by enabling rapid, on-site testing without the need for centralized laboratory infrastructure. This review presents recent advances in aptamer-functionalized nanoparticles (AFNs) as promising tools for enhancing POC diagnostics, particularly in infectious diseases and cancer. Aptamers, with their high specificity, stability, and modifiability, offer significant advantages over antibodies, while nanoparticles contribute multifunctionality, including signal amplification and targeting capabilities. AFNs have demonstrated up to a 2–10 times increase in detection sensitivity and significant reductions in diagnostic timeframes. We discuss various nanoparticle types, conjugation strategies, real-world applications, and highlight innovative developments such as AI-assisted aptamer design, wearable diagnostic devices, and green nanoparticle synthesis. Challenges related to stability, manufacturing scalability, regulatory hurdles, and clinical translation are critically examined. By merging aptamer precision with nanoparticle versatility, AFNs hold transformative potential to deliver rapid, affordable, and decentralized healthcare solutions, especially in resource-limited settings. Future interdisciplinary research and sustainable practices will be pivotal in translating AFN-based diagnostics from promising prototypes to global healthcare standards.
- 9 January 2025
- Published by Oxford University Press (OUP) in Biology Methods and Protocols
- Vol. 10 (1)
Open AccessAdvances and future directions of aptamer-functionalized nanoparticles for point-of-care diseases diagnosis
Point-of-care (POC) diagnostics have revolutionized disease detection by enabling rapid, on-site testing without the need for centralized laboratory infrastructure. This review presents recent advances in aptamer-functionalized nanoparticles (AFNs) as promising tools for enhancing POC diagnostics, particularly in infectious diseases and cancer. Aptamers, with their high specificity, stability, and modifiability, offer significant advantages over antibodies, while nanoparticles contribute multifunctionality, including signal amplification and targeting capabilities. AFNs have demonstrated up to a 2–10 times increase in detection sensitivity and significant reductions in diagnostic timeframes. We discuss various nanoparticle types, conjugation strategies, real-world applications, and highlight innovative developments such as AI-assisted aptamer design, wearable diagnostic devices, and green nanoparticle synthesis. Challenges related to stability, manufacturing scalability, regulatory hurdles, and clinical translation are critically examined. By merging aptamer precision with nanoparticle versatility, AFNs hold transformative potential to deliver rapid, affordable, and decentralized healthcare solutions, especially in resource-limited settings. Future interdisciplinary research and sustainable practices will be pivotal in translating AFN-based diagnostics from promising prototypes to global healthcare standards.
- Open Access
- 1 May 2024
- Published by Taylor & Francis in Journal of Experimental Pharmacology
- Vol. ume 16, 211-219
Ameliorative Effect of Faidherbia albida Against 2.4-Dinitrophenylhydrazine Induced Hyperbilirubinemia in Wistar Albino Rats
Background: Faidherbia albida, popularly known as gawo in Hausa, is traditionally used to treat jaundice in Zuru emirate of Kebbi State. Herein, the ameliorative effect of F. albida against 2.4-dinitrophenylhydrazine-induced hyperbilirubinemia in Wistar albino rats was investigated. Methods: Thirty healthy rats were administered 75 mg of 2.4-dinitrophenylhydrazine to induce hyperbilirubinemia. Thereafter, groups 1– 3 received 500, 750, and 1000 mg/kg body weight of the methanol stem-bark extract, and 15 mg/kg of phenobarbitone (standard drug) was administered to group 4. Groups 5 and 6 served as the untreated and normal controls, respectively. The phytochemical composition was evaluated using standard methods, and acute oral toxicity was evaluated using standard OECD 2008 guidelines. Results: Phytochemical analysis revealed the presence of alkaloids, phenols, and a substantial amount of tannins. A significant (P< 0.05) reduction of direct bilirubin, total bilirubin, and total protein levels for all the doses of the extract and standard drug compared to untreated groups was observed. Similarly, there were significant reductions in serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) levels of the group treated with the standard drug and all extract-treated groups compared to elevated levels observed in untreated controls. However, a significant (P< 0.05) increase in serum albumin (ALB) levels, red blood cells, hemoglobin, and pack cell volume was observed in all extract-treated compared to the untreated control in contrast to a significant decrease in MCH levels in treated groups compared to the untreated group. Conclusion: F. albida ameliorated the hyperbilirubinemia induced by 2.4-dinitrophenylhydrazine in Wistar albino rats, thus providing some support for its use in traditional medicine to treat jaundice.
- 1 May 2024
- Published by Taylor & Francis in Journal of Experimental Pharmacology
- Vol. ume 16, 211-219
Open AccessAmeliorative Effect of Faidherbia albida Against 2.4-Dinitrophenylhydrazine Induced Hyperbilirubinemia in Wistar Albino Rats
Background: Faidherbia albida, popularly known as gawo in Hausa, is traditionally used to treat jaundice in Zuru emirate of Kebbi State. Herein, the ameliorative effect of F. albida against 2.4-dinitrophenylhydrazine-induced hyperbilirubinemia in Wistar albino rats was investigated. Methods: Thirty healthy rats were administered 75 mg of 2.4-dinitrophenylhydrazine to induce hyperbilirubinemia. Thereafter, groups 1– 3 received 500, 750, and 1000 mg/kg body weight of the methanol stem-bark extract, and 15 mg/kg of phenobarbitone (standard drug) was administered to group 4. Groups 5 and 6 served as the untreated and normal controls, respectively. The phytochemical composition was evaluated using standard methods, and acute oral toxicity was evaluated using standard OECD 2008 guidelines. Results: Phytochemical analysis revealed the presence of alkaloids, phenols, and a substantial amount of tannins. A significant (P< 0.05) reduction of direct bilirubin, total bilirubin, and total protein levels for all the doses of the extract and standard drug compared to untreated groups was observed. Similarly, there were significant reductions in serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) levels of the group treated with the standard drug and all extract-treated groups compared to elevated levels observed in untreated controls. However, a significant (P< 0.05) increase in serum albumin (ALB) levels, red blood cells, hemoglobin, and pack cell volume was observed in all extract-treated compared to the untreated control in contrast to a significant decrease in MCH levels in treated groups compared to the untreated group. Conclusion: F. albida ameliorated the hyperbilirubinemia induced by 2.4-dinitrophenylhydrazine in Wistar albino rats, thus providing some support for its use in traditional medicine to treat jaundice.
- Open Access
- 1 January 2024
- Published by Oxford University Press (OUP) in RPS Pharmacy and Pharmacology Reports
- Vol. 3 (1)
A review of the medicinal uses and biological activity of Piliostigma thonningii (Schum). Milne-Redh.
Piliostigma thonningii is a medicinal plant commonly found in Eastern and Western Africa with a potential traditional usage to treat various diseases. Several studies have revealed interesting pharmacological activities of the plant and different phytochemicals were identified. This study critically reviewed the medicinal uses, phytochemistry, and bioactivity of P. thonningii. Relevant databases including ISI Web of Knowledge, Science Direct, Scopus, PubMed, and Google Scholar as well as databases for theses were searched for information using the keyword P. thonningii and its synonym. P. thonningii is majorly prepared in Africa as a decoction, infusion, maceration, and ointment and administered orally or topically to treat several diseases such as malaria, cancer, hepatitis, diabetes, and others. Pharmacological studies have demonstrated activities including antimalarial, antiviral, antimicrobial, anti-proliferative, and other medicinal properties. Compounds including piliostigmin, C-methyl flavonols, quercetin, and others were among the active components. The general use of P. thonnigii in various medicinal forms in Africa presents a great opportunity for the development of innovative research toward the production of natural products and nutraceuticals. Nevertheless, additional studies especially in vivo are necessary to further elucidate the mechanism mediating the bioactivities, especially in relation to the medicinal and nutritional uses.
- 1 January 2024
- Published by Oxford University Press (OUP) in RPS Pharmacy and Pharmacology Reports
- Vol. 3 (1)
Open AccessA review of the medicinal uses and biological activity of Piliostigma thonningii (Schum). Milne-Redh.
Piliostigma thonningii is a medicinal plant commonly found in Eastern and Western Africa with a potential traditional usage to treat various diseases. Several studies have revealed interesting pharmacological activities of the plant and different phytochemicals were identified. This study critically reviewed the medicinal uses, phytochemistry, and bioactivity of P. thonningii. Relevant databases including ISI Web of Knowledge, Science Direct, Scopus, PubMed, and Google Scholar as well as databases for theses were searched for information using the keyword P. thonningii and its synonym. P. thonningii is majorly prepared in Africa as a decoction, infusion, maceration, and ointment and administered orally or topically to treat several diseases such as malaria, cancer, hepatitis, diabetes, and others. Pharmacological studies have demonstrated activities including antimalarial, antiviral, antimicrobial, anti-proliferative, and other medicinal properties. Compounds including piliostigmin, C-methyl flavonols, quercetin, and others were among the active components. The general use of P. thonnigii in various medicinal forms in Africa presents a great opportunity for the development of innovative research toward the production of natural products and nutraceuticals. Nevertheless, additional studies especially in vivo are necessary to further elucidate the mechanism mediating the bioactivities, especially in relation to the medicinal and nutritional uses.